Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark B Abelson

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
The Ocular Surface|August 18, 2010
Personal profile. Mark B. Abelson, MD, CM, FRCSCMark B Abelson
Expert Opinion on Pharmacotherapy|August 28, 2004
A review of olopatadine for the treatment of ocular allergyMark B Abelson
Current Allergy and Asthma Reports|June 7, 2003
Conjunctival allergen challenge: models in the investigation of ocular allergyMark B Abelson, Oliver Loeffler
Clinical Therapeutics|July 11, 2003
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitisMark B Abelson, Darell Turner
Clinical Therapeutics|December 12, 2003
Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humansAndrea Leonardi, Mark B Abelson
Current Allergy and Asthma Reports|July 11, 2006
Ocular allergy in pediatric practiceMark B Abelson, David Granet
The Journal of Allergy and Clinical Immunology|January 8, 2005
Allergic conjunctivitis: update on pathophysiology and prospects for future treatmentSanta Jeremy Ono, Mark B Abelson
Current Medical Research and Opinion|February 11, 2005
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge modelMark B Abelson, Jack V Greiner
Expert Review of Clinical Immunology|May 19, 2010
Pharmacology, clinical efficacy and safety of olopatadine hydrochlorideSteven J Lichtenstein, Mark B Abelson
Clinical Therapeutics|April 16, 2002
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge modelMark B Abelson, Allen P Kaplan
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
The Ocular Surface|August 18, 2010
Personal profile. Mark B. Abelson, MD, CM, FRCSCMark B Abelson
Expert Opinion on Pharmacotherapy|August 28, 2004
A review of olopatadine for the treatment of ocular allergyMark B Abelson
Current Allergy and Asthma Reports|June 7, 2003
Conjunctival allergen challenge: models in the investigation of ocular allergyMark B Abelson, Oliver Loeffler
Clinical Therapeutics|July 11, 2003
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitisMark B Abelson, Darell Turner
Clinical Therapeutics|December 12, 2003
Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humansAndrea Leonardi, Mark B Abelson
Current Allergy and Asthma Reports|July 11, 2006
Ocular allergy in pediatric practiceMark B Abelson, David Granet
The Journal of Allergy and Clinical Immunology|January 8, 2005
Allergic conjunctivitis: update on pathophysiology and prospects for future treatmentSanta Jeremy Ono, Mark B Abelson
Current Medical Research and Opinion|February 11, 2005
Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge modelMark B Abelson, Jack V Greiner
Expert Review of Clinical Immunology|May 19, 2010
Pharmacology, clinical efficacy and safety of olopatadine hydrochlorideSteven J Lichtenstein, Mark B Abelson
Clinical Therapeutics|April 16, 2002
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge modelMark B Abelson, Allen P Kaplan
Pageof 7